Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Nanopath

Nanopath raises $25M to run the FDA study for its 15-minute vaginitis test

Norwest and SV Health Investors' MedTech Convergence Fund co-led the Series B, with Labcorp's venture fund taking part. The money funds manufacturing scale-up and the clinical study Nanopath needs for a 510(k) submission.

Charted Staff2 min read
From a company announcement published Nov. 10, 2026, and an earlier company announcement published Nov. 18, 2025
A patient exam room at an urgent care clinic and doctor's office in North Carolina.
A patient exam room at an urgent care clinic and doctor's office in North Carolina. File photo.Harrison Keely / Wikimedia Commons (CC BY 4.0)
Amount
$25M
Type
Series B
Company
Nanopath
Led by
Norwest, SV Health Investors' MedTech Convergence Fund
Sector
Diagnostics
Announced
Nov. 10, 2026

Nanopath's pitch is that molecular testing for infections should not have to leave the clinic. The company is building molecular tests meant to return results during a single visit, and on Nov. 10 it said it had raised $25 million to take its first one into the clinical study it needs for a Food and Drug Administration filing.

The Cambridge, Mass., company said its Series B includes $2 million of non-dilutive grant money. Norwest and SV Health Investors' MedTech Convergence Fund co-led the round, and the Labcorp Venture Fund joined as a strategic investor. Elderberry Ventures, GingerBread Capital and Alumni Ventures also took part. Nanopath did not disclose a valuation.

Why it matters: The money moves Nanopath from development toward a regulatory filing for what it describes as a 15-minute point-of-care molecular test for vaginitis. Labcorp's venture fund is in the round, and a Labcorp Diagnostics executive has joined the board as an observer.

Catherine Kiani, managing partner at Elderberry Ventures, and Mindy Nye, a vice president at Labcorp Diagnostics, joined Nanopath's board as observers, the company said.

What the money is for

Nanopath said the funding will support steps toward a possible commercial launch of the vaginitis assay, including scaling up manufacturing and starting the clinical study for a 510(k) submission to the FDA. It also plans to hire for clinical and commercial roles ahead of a launch.

The FDA has not cleared or approved the test, which is still in development, the company said, and commercial availability depends on finishing development and regulatory review. Nanopath said the round also supports a possible move into tests for urinary tract infections and sexually transmitted infections.

Nanopath already holds an FDA designation in that area. In November 2025, the agency granted Breakthrough Device designation to a Nanopath assay meant to quickly detect complicated urinary tract infections in patients who are suspected of having one or are at risk. Nanopath said that test is designed to pick out the organisms causing the infection, along with markers of antibiotic resistance, directly from urine in about 15 minutes.

"This funding brings us closer to the next and most important step," said Alison Burklund, Nanopath's co-founder and co-chief executive. Amogha Tadimety is the other co-founder and co-CEO.

The technology

Nanopath says its platform is built on plasmonic biosensing, an optical method that the company says can detect molecular targets without the nucleic acid amplification step that PCR-based tests need. The company wants high-complexity testing to happen where patients are seen instead of at central labs.

Jeff Crowe, senior managing partner at Norwest, said the firm planned to keep backing the company "at this key inflection point."

Labcorp is also adding women's health testing through an acquisition. In October, the company agreed to buy BioReference Health's clinical, women's health and other testing businesses from Opko Health for $722 million in cash.

Funding to date

Nanopath was founded in 2020 and is based at The Engine, the startup facility built by MIT, according to the release. The company said it has raised over $46 million in total.

What to watch

Nanopath did not say when the 510(k) study will start, how many patients it will enroll or when it expects to file. Those milestones, and whether the UTI test moves forward under its Breakthrough designation, will show how quickly the platform can reach clinics.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.